Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure
Acadia Pharmaceuticals has discontinued development of intranasal carbetocin for Prader-Willi syndrome (PWS) after its Phase 3 COMPASS PWS trial missed the primary endpoint7.
The 12-week, randomized, placebo-controlled global trial evaluated the efficacy and safety of the carbetocin nasal spray in individuals aged 5–30 years with PWS, seeking to reduce hyperphagia (extreme hunger)35.
The trial found no statistically significant improvement over placebo in reduction of hyperphagia symptoms, as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT)35.
The safety profile of carbetocin nasal spray was generally consistent with previous studies, with a low rate of adverse events35.
Due to these negative efficacy results, Acadia announced it would not pursue further development of intranasal carbetocin for this indication7.
Sources:
3. https://www.nasdaq.com/articles/acadia-pharmaceuticals-phase-3-compass-pws-trial-misses-primary-endpoint
5. https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial